Preventing Infections with Acalabrutinib Plus Venetoclax
July 29, 2025
An ongoing phase 2 clinical trial is studying whether preemptive acalabrutinib plus venetoclax can prevent infections in newly diagnosed CLL patients.
An ongoing phase 2 clinical trial is studying whether preemptive acalabrutinib plus venetoclax can prevent infections in newly diagnosed CLL patients.
People with CLL and SLL are at higher risk of developing infections due to having weakened immune systems.
People with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are at higher risk of developing infections due to having weakened immune systems.
Join CLL Society and Dr. Veronica Dioverti as we discuss the present status of the COVID-19 pandemic, as well as RSV, influenza, and pneumonia.
Dr. William Werbel will discuss the most common infections seen in people with CLL, why they occur, and what steps can be taken to prevent and manage them
Join CLL Society and Dr. William Werbel for an in-depth discussion on managing infection risks. We’ll explore respiratory and other significant infections, review essential infection control measures including reactivation of prior infections, discuss treatment options, vaccinations, and outline special precautions that are necessary to help protect those who are immunocompromised.
Here is a list of personal reflections on what we know and don’t know about COVID-19 and other infections that all immunocompromised folks might want to consider moving forward into the brave new world of increased respiratory infection risk.
Because patients with CLL / SLL are living longer, they are facing other emerging health challenges that are reviewed in this article.
Clinician Resource Library: Informational Handouts Click below on each of the topical handouts to view and print copies on demand. You may also order a free Welcome Kit which includes a